February 2025 - Page 10 of 34

Study Highlights Socioeconomic Barriers in Access to Allo-HCT for AML Patients

By Mourabit Halima 2025.02.21

A study published in Blood on November 5, 2024, reveals how socioeconomic factors influence access to allogeneic hematopoietic cell transplantation (allo-HCT) for acute myeloid leukemia (AML) patients. The findings indicate…

New Potential Treatment for Sickle Cell Disease: IMA001 Shows Promise

By Mourabit Halima 2025.02.21

Presented on November 5, 2024, new research highlights the potential of IMA001 as a novel therapeutic approach for Sickle Cell Disease (SCD). The study demonstrated that IMA001 significantly reduced red…

New Findings on Blinatumomab for Childhood B-Cell Acute Lymphoblastic Leukemia (B-Cell ALL)!

By Mourabit Halima 2025.02.20

On December 7, 2024, a phase 3 trial published in The New England Journal of Medicine provided compelling evidence on the addition of blinatumomab to chemotherapy in children with newly…

News of ASH：Application of the Ketogenic Diet in CAR-T Therapy

By Mourabit Halima 2025.02.20

The 66th American Society of Hematology (ASH) Annual Meeting has successfully concluded, bringing together over 30,000 experts and scholars worldwide. Through meticulously curated sessions, the conference provided profound insights into fundamental research, innovative therapies, and disease management in hematology. To highlight the latest developments, Hematology Frontier presents the News of ASH series, offering key takeaways from ASH’s official reports.

Unlocking the Prognostic Power of ctDNA in Colorectal Cancer: Insights from a Landmark Study

By Peng Longmei 2025.02.20

Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, with recurrence after treatment posing a significant challenge. The CALGB/SWOG 80702 trial explored the potential of circulating tumor DNA (ctDNA)…

News of ASH：Gut Microbiota and CAR-T Therapy

By Peter W. PENG 2025.02.20

The 66th American Society of Hematology (ASH) Annual Meeting has successfully concluded, bringing together over 30,000 experts and scholars worldwide. Through meticulously curated sessions, the conference provided valuable insights into fundamental research, innovative therapies, and disease management in hematology. To distill the essence of ASH and capture the latest advancements in the field, Hematology Frontier launched the News of ASH series, compiling key takeaways from ASH's official reports to present cutting-edge developments and significant discoveries to readers.

News of ASH：Overview of Acute Myeloid Leukemia Research Advances in 2024

By El Bachir MOURABIT 2025.02.20

The 66th American Society of Hematology (ASH) Annual Meeting has successfully concluded, gathering over 30,000 experts and scholars from around the world. This year’s conference featured numerous carefully curated sessions, providing profound insights into fundamental research, innovative therapies, and disease management in hematology. To highlight the key findings from ASH 2024, Hematology Frontier presents the News of ASH series, offering a concise summary of the latest breakthroughs in the field.

Revolutionizing Treatment for MSI-H/dMMR Metastatic Colorectal Cancer: The Promising Results of the CheckMate 8HW Trial

By Mourabit Halima 2025.02.20

The CheckMate 8HW trial, presented at the ASCO Gastrointestinal Cancers Symposium by Thierry Andre, is a randomized, multicenter, open-label phase 3 study evaluating the efficacy and safety of nivolumab (NIVO)…

ASCO GU 2025 | Dr. Xuefeng Qiu and Dr. Darren Poon：Advancing Precision Medicine in Prostate Cancer

By Mourabit Halima 2025.02.20

The 2025 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2025) has already taken place in San Francisco, USA. This globally renowned academic event brought together top oncology scholars to jointly explore the cutting-edge breakthroughs and future directions in the field of genitourinary oncology.In this insightful exchange, Dr. Xuefeng Qiu from the Nanjing Drum Tower Hospital and Dr. Darren Poon from the Hong Kong Sanatorium and Hospital Comprehensive Cancer Center,China discuss key advances in mCRPC treatment, focusing on PARP inhibitors, ARPIs, and radioligand therapy. While genomic testing is shaping precision medicine, uncertainties remain regarding the benefit of PARP-ARPI combinations in ARPI-refractory patients. Dr. Poon highlights the potential of lutetium-177 PSMA therapy, especially for patients without prior chemotherapy.As precision oncology evolves, balancing efficacy, toxicity, and quality of life remains crucial. We appreciate our experts' insights and look forward to continued progress in prostate cancer treatment.

ASCO GU 2025 | Professors Jun Guo, Xinan Sheng, and Bixia Tang: Chinese Innovative Drugs Enter the Global Stage, Expanding the Benefits in Urothelial

By Mourabit Halima 2025.02.20

With the rapid advancement of ADC-based combination immunotherapies globally, the treatment landscape for advanced urothelial carcinoma has undergone a dramatic transformation, leading to multiple updates in clinical guidelines. This year’s ASCO Genitourinary Cancers Symposium (ASCO GU) was held from February 13–15 in San Francisco, where Professor Jun Guo from Peking University Cancer Hospital led a team of researchers. Professors Xinan Sheng and Bixia Tang presented two pivotal studies on Chinese innovative drugs for urothelial carcinoma, gaining international recognition.Urology Frontier invited the Peking University Cancer Hospital team to discuss key breakthroughs, ongoing challenges in the diagnosis and treatment of urothelial carcinoma, the results of the SHR-A2102 study, and the efficacy and patient benefits of RC48 in combination with toripalimab.